• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Syapse Expands Precision Medicine to Asia Through Partnership With Health System

by Fred Pennic 01/31/2018 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Syapse

Syapse, a precision medicine company, announced today it is expanding to Asia through new partnerships with Seoul National University Hospital (SNUH), the premier hospital in Korea, and Megazone, a cloud-specialized IT company.

Syapse and SNUH are launching a precision oncology program to improve cancer care in Korea, with the support of Megazone’s innovative cloud services. SNUH, one of the largest health systems in South Korea, is the first health system outside the U.S. to use the Syapse platform. Through the new partnership, physicians at SNU Cancer Hospital’s 28 centers will use Syapse’s point-of-care software platform to deliver more effective, personalized cancer therapies. Syapse’s software enables oncologists to implement large-scale precision medicine by integrating the clinical, molecular, and outcomes data they need to make the most informed treatment decisions.

SNU Cancer Hospital, opened in March 2011 and based in Seoul, is dedicated to providing the best medical services to cancer patients. The hospital includes 16 Cancer Specialty Centers, 10 Multidisciplinary Cancer Treatment Centers, and a Cancer Clinical Trials Center.

With precision medicine, physicians at SNUH will be able to deliver precision care based on a patient’s clinical and genomic profile, an approach that has been shown to improve outcomes, lower costs, and increase efficiency. SNUH will join the Syapse network of leading providers, such as Providence St. Joseph Health and Aurora Health Care in the U.S., that benefit from real-world insights into which treatments are most effective.Syapse’s expansion into Asia will be accelerated through its multi-year partnership with Megazone. This partnership will bring precision medicine to health systems and patients throughout the Asia-Pacific region, initially focusing on Korea, Japan, and Vietnam.

“Syapse gives us a powerful platform to make effective cancer treatment decisions by using molecular analysis technology,” said Kyung Hwan Kim, M.D., Thoracic and Cardiovascular Surgery, Chief Information Officer of SNUH in a statement. “And through our precision medicine platform, we hope Seoul National University Hospital will provide a new standard for the evidence-based precision treatment of cancer.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Cancer Big Data, Evidence-based medicine, Precision Medicine, Precision Medicine Oncology, Syapse

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |